Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

NCT ID: NCT03486873

This clinical trial, called MK-3475-587, is looking into the long-term safety and effectiveness of a treatment called pembrolizumab (also known as MK-3475) for patients with advanced tumors. If you...

Recruiting

Phase: PHASE3 Conditions: Solid Tumors, Hematologic Malignancies

Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)

NCT ID: NCT06074588

This clinical trial is studying a new treatment called sacituzumab tirumotecan for patients with advanced or metastatic non-small cell lung cancer (NSCLC) that has specific genetic changes, such as...

Recruiting

Phase: PHASE3 Conditions: Non-small Cell Lung Cancer (NSCLC)

Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)

NCT ID: NCT06132958

This clinical trial is studying a new treatment called MK-2870, also known as sacituzumab tirumotecan, for women with endometrial cancer who have already received certain types of treatments. These...

Recruiting

Phase: PHASE3 Conditions: Endometrial Cancer

A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)

NCT ID: NCT06428409

This clinical trial is investigating a new treatment called sacituzumab tirumotecan (MK-2870) to see how well it works alone or in combination with chemotherapy for certain advanced gastrointestina...

Recruiting

Phase: PHASE1 Conditions: Colorectal Cancer, Pancreatic Ductal Adenocarcinoma +1 more

A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)

NCT ID: NCT06305767

This clinical trial is studying a new treatment approach for people with high-risk muscle-invasive urothelial carcinoma (MIUC), a serious type of bladder cancer. The researchers want to find out if...

Recruiting

Phase: PHASE1 Conditions: Bladder Cancer

A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)

NCT ID: NCT06430801

This clinical trial is studying a new medication called tulisokibart, which is being tested for its effectiveness and safety in treating people with moderate to severe Crohn's disease. Crohn's dise...

Recruiting

Phase: PHASE3 Conditions: Crohn's Disease

A Study of MK-1084 in KRAS Mutant Advanced Solid Tumors (MK-1084-001)

NCT ID: NCT05067283

This clinical trial, titled "A Study of MK-1084 in KRAS Mutant Advanced Solid Tumors," is investigating a new treatment called MK-1084 for patients with advanced solid tumors that have a specific g...

Recruiting

Phase: PHASE1 Conditions: Advanced Solid Tumors

Efficacy And Safety Of MK-6194 In Adult Participants With Systemic Lupus Erythematosus (MK-6194-006)

NCT ID: NCT06161116

This clinical trial is studying a new treatment called MK-6194 for adults with Systemic Lupus Erythematosus (SLE), a condition where the immune system mistakenly attacks healthy tissues. The main g...

Recruiting

Phase: PHASE2 Conditions: Systemic Lupus Erythematosus

A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)

NCT ID: NCT06136650

This clinical trial is studying a new medication called opevesostat (MK-5684) to see how well it works when combined with hormone replacement therapy (HRT) for men with metastatic castration-resist...

Recruiting

Phase: PHASE3 Conditions: Prostatic Neoplasms, Metastatic Castration-resistant Prostate Cancer (mCRPC)

Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)

NCT ID: NCT06353386

This clinical trial, named Substudy 01A, is exploring whether a new treatment called opevesostat, either on its own or combined with other therapies, is safe and effective for men with metastatic c...

Recruiting

Phase: PHASE1 Conditions: Prostatic Neoplasms, Castration-Resistant

Pan Tumor Rollover Study

NCT ID: NCT03899155

The Pan Tumor Rollover Study is a clinical trial focused on understanding the long-term safety of a cancer treatment called nivolumab, both on its own and in combination with other therapies. This ...

Recruiting

Phase: PHASE2 Conditions: Cancer

Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

NCT ID: NCT06236438

This clinical trial is studying a new treatment approach for adults with untreated metastatic non-squamous non-small cell lung cancer (NSCLC), which is a serious type of lung cancer. Researchers wa...

Recruiting

Phase: PHASE2 Conditions: Non-Small Cell Lung Cancer

A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)

NCT ID: NCT06356311

This clinical trial is studying a new treatment called sacituzumab tirumotecan (MK-2870) for patients with advanced or metastatic gastroesophageal adenocarcinoma, which is a type of cancer affectin...

Recruiting

Phase: PHASE3 Conditions: Gastroesophageal Cancer

Main Menu

Clinical Trials in Temuco, Araucania

13 Active Trials Found in Temuco

Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)

Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)

A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)

A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)

A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)

A Study of MK-1084 in KRAS Mutant Advanced Solid Tumors (MK-1084-001)

Efficacy And Safety Of MK-6194 In Adult Participants With Systemic Lupus Erythematosus (MK-6194-006)

A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)

Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)

Pan Tumor Rollover Study

Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)